Rocket Pharmaceuticals, Inc. Common Stock

RCKTNASDAQ • USD
ThemeGenomics & Precision Med.›Gene Therapy & Gene Editing
3.25 USD
↗ 0.01 (0.31%)AT CLOSE (11:59 AM EDT)
3.28
↗ 0.03 (0.77%)
POST MARKET (AS OF 07:59 PM EDT)
Post Market
AS OF 07:59 PM EDT
3.28
↗ 0.03 (0.77%)
🔴Market: CLOSED

Rocket Pharmaceuticals, Inc. Common Stock (RCKT) trades at $3.25 per share. RCKT shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. The stock looks compelling on valuation, with multiples below sector averages across P/E, P/B, and EV/EBITDA.

Technical & fundamental data as of Jun 26, 2026.

Open?$3.24
High?$3.40
Low?$3.08
Prev. Close?$3.24
Volume?7.7M
Avg. Volume?2.9M
VWAP?$3.23
Rel. Volume?2.63x
Bid / Ask
Bid?$2.62 × 100
Ask?$3.88 × 100
Spread?$1.26
Midpoint?$3.25
Valuation & Ratios
Market Cap?354.9M
Shares Out?109.2M
Float?84.0M
Float %?77.0%
P/E Ratio?N/A
P/B Ratio?1.49
EPS?-$1.92
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Themes
Healthcare - Genomics & Precision Medicine›Gene Therapy & Gene EditingBiotech - Drug Development›Rare Disease Therapeutics
Employees
202
Market Cap
353.8M
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.rocketpharma.com
Listed
2015-02-18
Address
350 FIFTH AVENUE
NEW YORK, NY 10118
Phone: 646-440-9100
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+1/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
36
Piotroski F-Score?0/9Weak
Altman Z-Score?-4.78Distress
Confidence?56%Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?26.06%Squeeze Risk
Short Interest?21.9M
Days to Cover?8.4
Free Float84.0M
Avg Daily Volume2.6M
Settlement Date2026-06-15
Financial Health
Current Ratio?6.12Strong
Quick Ratio?6.12Strong
Cash Ratio?2.03Strong
Debt/Equity?0.09Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
87
1.49CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.6CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-88.0%WEAK▾
ROA?
S&P
3
-73.4%WEAK▾
Cash Flow & Enterprise
FCF?$-179787000
Enterprise Value?$326.5M
Fundamentals ratios updated end of day
MarketsMoversWatchlist